Immunic, Inc. (NASDAQ:IMUX) Sees Large Decline in Short Interest

Immunic, Inc. (NASDAQ:IMUX) was the target of a significant decrease in short interest in July. As of July 31st, there was short interest totalling 2,690,000 shares, a decrease of 8.8% from the July 15th total of 2,950,000 shares. Based on an average daily trading volume, of 287,700 shares, the days-to-cover ratio is currently 9.4 days.

Analyst Upgrades and Downgrades

IMUX has been the topic of several recent research reports. StockNews.com raised shares of Immunic from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. Piper Sandler reiterated an “overweight” rating and issued a $28.00 price objective on shares of Immunic in a report on Tuesday, July 16th.

Immunic Stock Down 2.2 %

Shares of Immunic stock traded down $0.03 on Friday, hitting $1.32. The stock had a trading volume of 113,899 shares, compared to its average volume of 559,227. The stock’s 50-day simple moving average is $1.26 and its two-hundred day simple moving average is $1.28. Immunic has a one year low of $0.95 and a one year high of $1.92. The stock has a market cap of $118.90 million, a price-to-earnings ratio of -0.72 and a beta of 1.76.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. During the same quarter in the previous year, the firm posted ($0.54) earnings per share. As a group, equities analysts predict that Immunic will post -0.94 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC bought a new stake in shares of Immunic in the 1st quarter worth approximately $9,266,000. Sierra Summit Advisors LLC purchased a new stake in Immunic in the fourth quarter worth $487,000. Gratus Capital LLC boosted its holdings in Immunic by 15.1% in the fourth quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock valued at $2,912,000 after acquiring an additional 254,999 shares in the last quarter. Ikarian Capital LLC increased its position in Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after purchasing an additional 1,162,378 shares during the period. Finally, Vanguard Group Inc. raised its holdings in Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after purchasing an additional 1,703,047 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.